Rare Diseases Report 2022

The broad and challenging – but promising – landscape of peripheral neuropathy


 

Therapeutic options

There are no FDA-approved treatments for CSPN, as most treatments are geared toward neuropathic pain management, rehabilitation, and supportive care.68 Due to a lack of research and data regarding these types of peripheral neuropathies, various studies suggest different first-line therapies. For example, anticonvulsants (pregabalin, gabapentin), antidepressants (duloxetine), and opioid-like compounds (tramadol) are all threapy options to treat DPN.3

Adequate data are lacking to support the efficacy of immunosuppressive therapy in CSPN.

Pages

Recommended Reading

High early recurrence rates with Merkel cell carcinoma
MDedge Hematology and Oncology
Dodging potholes from cancer care to hospice transitions
MDedge Hematology and Oncology
Myositis guidelines aim to standardize adult and pediatric care
MDedge Hematology and Oncology
Quality of life benefit exaggerated in some cancer studies
MDedge Hematology and Oncology
FDA approves first gene therapy, betibeglogene autotemcel (Zynteglo), for beta-thalassemia
MDedge Hematology and Oncology
Erlotinib promising for cancer prevention in familial adenomatous polyposis
MDedge Hematology and Oncology
A farewell to arms? Drug approvals based on single-arm trials can be flawed
MDedge Hematology and Oncology
AAP guidance helps distinguish bleeding disorders from abuse
MDedge Hematology and Oncology
Cancer as a full contact sport
MDedge Hematology and Oncology
Lasker awardee pioneered prenatal DNA testing
MDedge Hematology and Oncology